शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

COHANCENSECOHANCE LIFESCIENCES LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 6 Nov, 2026 · 17:48 IST

Consolidated September quarter revenue down 14.2%; EBITDA margin falls to 7.4%

Revenue declinedEBITDA margin compressionResults View source PDFExplain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction

Awaiting price reaction for this filing.

AI summary

For the consolidated quarter ended 30 September 2026, revenue from operations was Rs 476.65 crore, down 14.2% from Rs 555.57 crore a year earlier, while profit after tax for shareholders was Rs 15.22 crore versus Rs 74.08 crore. Reported EBITDA margin fell to 7.4% from 22.1%. Consolidated half-year operating cash flow was Rs 188.06 crore. Management expects a stronger second half, but a fatal accident caused the Suryapet plant closure.

Likely market impact

Weaker revenue and EBITDA may hurt earnings and sentiment. Plant closure adds risk, though second-half recovery and cash generation offer support.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26
Q2 FY27Q2 FY26Change
Revenue₹476.7 Cr₹1,105 Cr−56.9%
Operating profit−₹23.16 Cr₹124.9 Cr−118.5%
Profit after tax₹2.27 Cr₹112.8 Cr−98.0%
EBITDA margin7.4%20.4%−12.9 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.